Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A new era of the Asian clinical research network: a report from the ATLAS international symposium.
Terada M, Nakamura K, Matsuda T, Okuma HS, Sudo K, Yusof A, Imasa M, Sirachainan E, Anh PT, Fujiwara Y, Yamamoto N, Voon PJ, Chokephaibulkit K, Shibata T, Inoue M, Mano H, Shimoi T, Sriuranpong V, Yonemori K, Shimada K. Terada M, et al. Among authors: yamamoto n. Jpn J Clin Oncol. 2023 Jun 29;53(7):619-628. doi: 10.1093/jjco/hyad033. Jpn J Clin Oncol. 2023. PMID: 37099440
A Phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small-cell lung cancer (JCOG1201).
Eba J, Shimokawa T, Nakamura K, Shibata T, Misumi Y, Okamoto H, Yamamoto N, Ohe Y; Lung Cancer Study Group of the Japan Clinical Oncology Group. Eba J, et al. Among authors: yamamoto n. Jpn J Clin Oncol. 2015 Jan;45(1):115-8. doi: 10.1093/jjco/hyu166. Epub 2014 Oct 20. Jpn J Clin Oncol. 2015. PMID: 25332420 Clinical Trial.
Study protocol for J-SUPPORT 1604 (J-FORCE): a randomized, double blind, placebo-controlled Phase III study evaluating olanzapine (5 mg) plus standard triple antiemetic therapy for prevention of chemotherapy induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy.
Hashimoto H, Abe M, Yanai T, Yamaguchi T, Zenda S, Uchitomi Y, Fukuda H, Mori M, Iwasa S, Yamamoto N, Ohe Y. Hashimoto H, et al. Among authors: yamamoto n. Jpn J Clin Oncol. 2018 Oct 1;48(10):950-952. doi: 10.1093/jjco/hyy114. Jpn J Clin Oncol. 2018. PMID: 30124989 Clinical Trial.
Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study.
Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A, Koyama T, Kakishima H, Kitami M, Matsushita H, Furukawa E, Narushima D, Nagai M, Taniguchi H, Motoi N, Sekine S, Maeshima A, Mori T, Watanabe R, Yoshida M, Yoshida A, Yoshida H, Satomi K, Sukeda A, Hashimoto T, Shimizu T, Iwasa S, Yonemori K, Kato K, Morizane C, Ogawa C, Tanabe N, Sugano K, Hiraoka N, Tamura K, Yoshida T, Fujiwara Y, Ochiai A, Yamamoto N, Kohno T. Sunami K, et al. Among authors: yamamoto n. Cancer Sci. 2019 Apr;110(4):1480-1490. doi: 10.1111/cas.13969. Epub 2019 Apr 2. Cancer Sci. 2019. PMID: 30742731 Free PMC article.
Improved survival among patients enrolled in oncology phase 1 trials in recent decades.
Ebata T, Shimizu T, Koyama T, Shimomura A, Iwasa S, Kondo S, Kitano S, Yonemori K, Fujiwara Y, Yamamoto N. Ebata T, et al. Among authors: yamamoto n. Cancer Chemother Pharmacol. 2020 Feb;85(2):449-459. doi: 10.1007/s00280-019-03992-2. Epub 2019 Nov 19. Cancer Chemother Pharmacol. 2020. PMID: 31745590 Clinical Trial.
6,252 results